Mangiferin alleviates cardiac inflammatory injury in spontaneously hypertensive rats by inhibiting the MCP-1/CCR2 signaling pathway

doi:10.5246/jcps.2023.06.039

Abstract

Abstract:

Hypertension is a low-grade inflammation state of the disease and often complicated by inflammation of the heart. Mangiferin (MGF), which is a natural glucosyl xanthone, has a strong anti-inflammatory activity. However, the effects of MGF on cardiac inflammatory injury in hypertension remain unclear. In the present study, we investigated the protective effects and mechanisms of MGF on cardiac inflammatory injury in spontaneously hypertensive rats (SHRs). Briefly, 10-week-old male SHRs and 10-week-old male normotensive Wistar-Kyoto (WKY) rats were used. MGF was used in SHRs at doses of 10, 20, and 40 mg/kg for 8 weeks consecutively. The systolic blood pressure (SBP) level was measured, and the cardiac tissues were collected for morphology, immunohistochemistry, ELISA, Western blotting analysis, and real-time reverse transcription PCR (RT-PCR) analysis. The results showed that the SBP level was increased significantly in the model group compared with the control group both before and after intragastric administration, the SHRs increased the SBP level spontaneously, and all doses of MGF showed no significant effect on the SBP level. Cardiac histomorphology showed that there was an apparent inflammatory injury in the model group. MGF significantly inhibited this injury. Meanwhile, MGF significantly inhibited the increased abundance of IL-6 and TNF-α in SHRs. Furthermore, MGF also significantly inhibited the increased expressions of MCP-1 and CCR2 at the protein and mRNA levels in SHRs. In conclusion, this study demonstrated that MGF did not decrease the SBP level of SHRs. However, MGF had a protective effect on cardiac inflammatory injury in SHRs, which might be mediated partly by inhibiting the expression of the MCP-1/CCR2 signaling pathway.

Key words: Mangiferin, MCP-1/CCR2 Signaling Pathway, Cardiac

Supporting:

Xiaoqin Hu, Xuefei Ding, Jiagang Deng, Erwei Hao, Zhengcai Du, Bei Zhou, Xuewen Zeng. Mangiferin alleviates cardiac inflammatory injury in spontaneously hypertensive rats by inhibiting the MCP-1/CCR2 signaling pathway[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(6): 460-472.

Figures/Tables 9

Table 1. SBP in various groups (mmHg).

Table 2. Effect of MGF on IL-6 and TNF-α contents in cardiac tissues of SHRs (ng/L).

References 51

[1]	Salomon, J.A.; Wang, H.D.; Freeman, M.K.; Vos, T.; Flaxman, A.D.; Lopez, A.D.; Murray, C.J.L. Healthy life expectancy for 187 countries, 1990-2010: a systematic analysis for the Global Burden Disease Study 2010. Lancet. 2012, 380, 2144–2162.
[2]	Messerli, F.H.; Grossman, E. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001, 38, E11.
[3]	Rabinovitch, M.; Guignabert, C.; Humbert, M.; Nicolls, M.R. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ. Res. 2014, 115, 165–175.
[4]	De Miguel, C.; Rudemiller, N.P.; Abais, J.M.; Mattson, D.L. Inflammation and hypertension: new understandings and potential therapeutic targets. Curr. Hypertens. Rep. 2015, 17, 507.
[5]	Pauletto, P.; Rattazzi, M. Inflammation and hypertension: the search for a link. Nephrol. Dial. Transplant. 2006, 21, 850–853.
[6]	Bautista, L.E.; Vera, L.M.; Arenas, I.A.; Gamarra, G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J. Hum. Hypertens. 2005, 19, 149–154.
[7]	Humbert, M.; Monti, G.; Brenot, F.; Sitbon, O.; Portier, A.; Grangeot-Keros, L.; Duroux, P.; Galanaud, P.; Simonneau, G.; Emilie, D. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 1995, 151, 1628–1631.
[8]	Lakoski, S.G.; Herrington, D.M.; Siscovick, D.M.; Hulley, S.B. C-reactive protein concentration and incident hypertension in young adults: the CARDIA study. Arch. Intern. Med. 2006, 166, 345–349.
[9]	Capers, Q. IV, Alexander, R.W.; Lou, P.P.; De Leon, H.; Wilcox, J.N.; Ishizaka, N.; Howard, A.B.; Taylor, W.R. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension. 1997, 30, 1397–1402.
[10]	Glowinska, B.; Urban, M.; Peczynska, J.; Florys, B. Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes. Metabolism. 2005, 54, 1020–1026.
[11]	Celik, T.; Iyisoy, A.; Kursaklioglu, H.; Kardesoglu, E.; Kilic, S.; Turhan, H.; Yilmaz, M.I.; Ozcan, O.; Yaman, H.; Isik, E.; Fici, F. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J. Hypertens. 2006, 24, 591–596.
[12]	Chrysohoou, C.; Pitsavos, C.; Panagiotakos, D.B.; Skoumas, J.; Stefanadis, C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA Study. Am. J. Hypertens. 2004, 17, 568–573.
[13]	McMaster, W.G.; Kirabo, A.; Madhur, M.S.; Harrison, D.G. Inflammation, immunity, and hypertensive end-organ damage. Circ. Res. 2015, 116, 1022–1033.
[14]	Trippodo, N.C.; Frohlich, E.D. Similarities of genetic (spontaneous) hypertension. Man and rat. Circ. Res. 1981, 48, 309–319.
[15]	Widy-Tyszkiewicz, E.; Scheel-Krüger, J.; Christensen, A.V. Spatial navigation learning in spontaneously hypertensive, renal hypertensive and normotensive Wistar rats. Behav. Brain Res. 1993, 54, 179–185.
[16]	Sun, L.; Gao, Y.H.; Tian, D.K.; Zheng, J.P.; Zhu, C.Y.; Ke, Y.; Bian, K. Inflammation of different tissues in spontaneously hypertensive rats. Acta Physiol. Sin. 2006, 58, 318–323.
[17]	Rodríguez-Iturbe, B.; Quiroz, Y.; Ferrebuz, A.; Parra, G.; Vaziri, N.D. Evolution of renal interstitial inflammation and NF-kappaB activation in spontaneously hypertensive rats. Am. J. Nephrol. 2004, 24, 587–594.
[18]	Barrios, V.; Escobar, C. Antihypertensive and organ-protective effects of benazepril. Expert Rev. Cardiovasc. Ther. 2010, 8, 1653–1671.
[19]	Lin, L.P.; Wang, J.; Kuang, X. Effect of benazepril on serum endothelin, nitric oxide and C-reactive protein in patients with type 2 diabetes mellitus. J. Clin. Res. 2008, 11, 2018–2020.
[20]	He, H.B.; Shi, M.Q.; Yang, X.Z.; Zeng, X.W.; Wu, L.M.; Li, L.D. Comparison of cardioprotective effects using salvianolic acid B and benazepril for the treatment of chronic myocardial infarction in rats. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 378, 311–322.
[21]	Li, Y.; Gong, Y.Q.; Zhang, W. New study progress of mangiferin At home. Guid. J. Tradit. Chin. Med. Pharm. 2015, 21, 92–96.
[22]	Sarkar, M. Evaluation of the Anti-Inflammatory Activity of Methanolic Leaf Extract of Mangifera indica L. (Anacardiaceae) in Rats. Int. J. Drug Dev. Res. 2015, 7, 21–25.
[23]	Pan, C.W.; Pan, Z.Z.; Hu, J.J.; Chen, W.L.; Zhou, G.Y.; Lin, W.; Jin, L.X.; Xu, C.L. Mangiferin alleviates lipopolysaccharide and D-galactosamine-induced acute liver injury by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation. Eur. J. Pharmacol. 2016, 770, 85–91.
[24]	Li, M.L.; Ma, H.L.; Yang, L.X.; Li, P. Mangiferin inhibition of proliferation and induction of apoptosis in human prostate cancer cells is correlated with downregulation of B-cell lymphoma-2 and upregulation of microRNA-182. Oncol. Lett. 2016, 11, 817–822.
[25]	Sekar, M. Molecules of interest - mangiferin - A review. Annu. Res. Rev. Biol. 2015, 5, 307–320
[26]	Benard, O.; Chi, Y.L. Medicinal properties of mangiferin, structural features, derivative synthesis, pharmacokinetics and biological activities. Mini Rev. Med. Chem. 2015, 15, 582–594.
[27]	Prabhu, S.; Jainu, M.; Sabitha, K.E.; Devi, C.S. Cardioprotective effect of mangiferin on isoproterenol induced myocardial infarction in rats. Indian J. Exp. Biol. 2006, 44, 209–215.
[28]	Hu, X.Q.; Yang, X.M.; Zeng, X.W.; Hao, E.W.; Qin, L.L.; Deng, J.G. The effect of mangiferin on spontaneously hypertensive rats’ heart, brain and kidney tissue morphology. Sci. Technol. Eng. 2012, 12, 6278–6281.
[29]	Yang, Z.; Weian, C.; Susu, H.; Hanmin, W. Protective effects of mangiferin on cerebral ischemia–reperfusion injury and its mechanisms. Eur. J. Pharmacol. 2016, 771, 145–151.
[30]	Zou, T.B.; Xia, E.Q.; He, T.P.; Huang, M.Y.; Jia, Q.; Li, H.W. Ultrasound-assisted extraction of Mangiferin from Mango (Mangifera indica L.) leaves using response surface methodology. Molecules. 2014, 19, 1411–1421.
[31]	Baldo, M.P.; Forechi, L.; Morra, E.A.S.; Zaniqueli, D.; Machado, R.C.; Lunz, W.; Rodrigues, S.L.; Mill, J.G. Long-term use of low-dose spironolactone in spontaneously hypertensive rats: effects on left ventricular hypertrophy and stiffness. Pharmacol. Rep. 2011, 63, 975–982.
[32]	Han, J.; Xuan, J.L.; Yang, J.R.; Li, W.; Zhao, M.Q. Effect and mechanisms of sesamin on attenuating renal fibrosis in spontaneously hypertensive rats. Chin. J. Clin. Pharmacol. Ther. 2016, 21, 16–22.
[33]	Dickey, J.S.; Gonzalez, Y.; Aryal, B.; Mog, S.; Nakamura, A.J.; Redon, C.E.; Baxa, U.; Rosen, E.; Cheng, G.; Zielonka, J.; Parekh, P.; Mason, K.P.; Joseph, J.; Kalyanaraman, B.; Bonner, W.; Herman, E.; Shacter, E.; Rao, V.A. Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model. PLoS One. 2013, 8, e70575.
[34]	Lin, W.Y.; Lin, Y.P.; Levin, R.M.; Chen, M.L. The relevance of immune responses to partial bladder outlet obstruction and reversal. Neurourol. Urodyn. 2017, 36, 1306–1312.
[35]	McAtee, C.P.; Seid, C.A.; Hammond, M.; Hudspeth, E.; Keegan, B.P.; Liu, Z.Y.; Wei, J.F.; Zhan, B.; Arjona-Sabido, R.; Cruz-Chan, V.; Dumonteil, E.; Hotez, P.J.; Bottazzi, M.E. Expression, purification, immunogenicity and protective efficacy of a recombinant nucleoside hydrolase from Leishmania donovani, a vaccine candidate for preventing cutaneous leishmaniasis. Protein Expr. Purif. 2017, 130, 129–136.
[36]	Fang, H.; Shuang, D.; Yi, Z.; Sheng, H.; Liu, Y. Up-regulated microRNA-155 expression is associated with poor prognosis in cervical cancer patients. Biomed. Pharmacother. 2016, 83, 64–69.
[37]	Kurdi, M.; Randon, J.; Cerutti, C.; Bricca, G. Increased expression of IL-6 and LIF in the hypertrophied left ventricle of TGR(mRen2)₂₇ and SHR rats. Mol. Cell Biochem. 2005, 269, 95–101.
[38]	Sanada, L.S.; da Rocha Kalil, A.L.; Tavares, M.R.; Neubern, M.C.M.; Salgado, H.C.; Fazan, V.P.S. Sural nerve involvement in experimental hypertension: morphology and morphometry in male and female normotensive Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR). BMC Neuroscienc. 2012, 13, 24.
[39]	Akira, S.; Hirano, T.; Taga, T.; Kishimoto, T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 1990, 4, 2860–2867.
[40]	Ouyang, W.J.; Rutz, S.; Crellin, N.K.; Valdez, P.A.; Hymowitz, S.G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 2011, 29, 71–109.
[41]	Sriramula, S.; Haque, M.; Majid, D.S.A.; Francis, J. Involvement of tumor necrosis factor-α in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension. 2008, 51, 1345–1351.
[42]	Timasheva, Y.R.; Nasibullin, T.R.; Zakirova, A.N.; Mustafina, O.E. Association of interleukin-6, interleukin-12, and interleukin-10 gene polymorphisms with essential hypertension in tatars from Russia. Biochem. Genet. 2008, 46, 64–74.
[43]	Teilmann, A.C.; Rozell, B.; Kalliokoski, O.; Hau, J.; Abelson, K.S.P. Carotid catheterization and automated blood sampling induce systemic IL-6 secretion and local tissue damage and inflammation in the heart, kidneys, liver and salivary glands in NMRI mice. PLoS One. 2016, 11, e0166353.
[44]	Osnes, L.T.N.; Westvik, Å.B.; Øvstebø, R.; Joø, G.B.; Okkenhaug, C.; Kierulf, P. Lipopolysaccharide activation of human monocytes mediated by CD14, results in a coordinated synthesis of tissue factor, TNF-α and IL-6. J. Endotoxin Res. 1995, 2, 27–35.
[45]	Liu, X.T.; Fang, S.C.; Liu, H.J.; Wang, X.G.; Dai, X.N.; Yin, Q.; Yun, T.W.; Wang, W.; Zhang, Y.M.; Liao, H.; Zhang, W.; Yao, H.H.; Chao, J. Role of human pulmonary fibroblast-derived MCP-1 in cell activation and migration in experimental silicosis. Toxicol. Appl. Pharmacol. 2015, 288, 152–160.
[46]	Zhou, X.L.; Lei, H.; Sun, Z.J. Participation of immune cells in klotho deficiency-induced salt-sensitive hypertension. FASEB J. 2015, 29, 667.3.
[47]	Bäck, M.; Hansson, G.K. Anti-inflammatory therapies for atherosclerosis. Nat. Rev. Cardiol. 2015, 12, 199–211.
[48]	Xu, Y.K.; Ke, Y.; Wang, B.; Lin, J.H. The role of MCP-1-CCR2 ligand-receptor axis in chondrocyte degradation and disease progress in knee osteoarthritis. Biol. Res. 2015, 48, 64.
[49]	Yan, C.H.; Song, X.M.; Yu, W.W.; Wei, F.; Li, H.; Lv, M.G.; Zhang, X.W.; Ren, X.B. Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects. Tumour Biol. 2016, 37, 8425–8435.
[50]	Wang, Y.P.; Zhu, M.J.; Xu, H.; Cui, L.; Liu, W.H.; Wang, X.X.; Shen, S.; Wang, D.H. Role of the monocyte chemoattractant protein-1/C-C chemokine receptor 2 signaling pathway in transient receptor potential vanilloid type 1 ablation-induced renal injury in salt-sensitive hypertension. Exp. Biol. Med. 2015, 240, 1223–1234.
[51]	Meerschaert, J.; Furie, M.B. The adhesion molecules used by monocytes for migration across endothelium include CD11a/CD18, CD11b/CD18, and VLA-4 on monocytes and ICAM-1, VCAM-1, and other ligands on endothelium. J. Immunol. 1995, 154, 4099–4112.